



StrataGraft®

allogeneic cultured keratinocytes and dermal
fibroblasts in murine collagen - dsat

Coding and reimbursement guide

The information contained in this document is provided for informational purposes only and represents no statement, promise, or guarantee by Mallinckrodt concerning levels of reimbursement, payment, or charge. Similarly, all codes are supplied for informational purposes only and represent no statement, promise, or guarantee by Mallinckrodt that these codes will be appropriate or that reimbursement will be made. It is not intended to increase or maximize reimbursement by any payer. We strongly recommend that you consult your payer organization with regard to its reimbursement policies.

You are ultimately responsible for determining the appropriate reimbursement strategies and billing codes.

This guide provides general coding information for StrataGraft®. Depending on the site of service and the type of payer, providers may be required to use different types of codes on their claims.

The following code sets are generally used by payers in the inpatient setting. Refer to specific payer and state guidelines for direction on appropriate code selection.

- **International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS) Codes**
- **International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) Codes**
- **Revenue Codes**
- **National Drug Codes (NDCs)**

This guide is available at StrataGraft.com. The information contained in this document is provided for informational purposes only and represents no statement, promise, or guarantee by Mallinckrodt concerning levels of reimbursement, payment, or charge. Similarly, all codes are supplied for informational purposes only and represent no statement, promise, or guarantee by Mallinckrodt that these codes will be appropriate or that reimbursement will be made. It is not intended to increase or maximize reimbursement by any payer. We strongly recommend that you consult your payer organization with regard to its reimbursement policies. **You are ultimately responsible for determining the appropriate reimbursement strategies and billing codes.**

ICD-10-PCS CODES^{1,2}

The Centers for Medicare & Medicaid Services granted the new technology add-on payment (NTAP) to StrataGraft. Hospitals can use the unique ICD-10-PCS code for procedures related to StrataGraft to receive the add-on payment for Medicare and dual-eligible (Medicare-Medicaid) fee-for-service or TRICARE inpatient cases. For nonqualifying facilities or patients, use of standard ICD-10-PCS codes is appropriate.

ICD-10-PCS code	Descriptor
-----------------	------------

XHRPXF7	Replacement of skin with bioengineered allogeneic construct, external approach, new technology group 7
----------------	--

INDICATION

StrataGraft® is an allogeneic cellularized scaffold product indicated for the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns).

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

- Do not use in patients with known allergies to murine collagen or products containing ingredients of bovine or porcine origin.

Please see additional Important Safety Information on page 7 and full [Prescribing Information](#).

ICD-10-CM DIAGNOSIS CODES^{3,4}

Burns are classified according to the depth of tissue injury as superficial (first-degree burns), partial-thickness (superficial), deep partial-thickness (second-degree burns), and full-thickness (third-degree burns). Additionally, ICD-10-CM further distinguishes between thermal and chemical burns (corrosions). StrataGraft is indicated for the treatment of thermal burns. Thermal burns are also classified by body site, extent (total body surface area and depth), and external cause.

Diagnosis Coding Steps:

1. Code for burn site and depth (T20-T25)
2. Code the extent of body surface involved (T31)
3. Code the external cause (X00-X19, X75-X77, X96-X98, Y92)

Notes:

- It is common that a patient will suffer from burns on multiple body sites. Each anatomical site should be identified using the appropriate code from T20-T25. Sequence first the code that reflects the burn of the highest degree
- If there are multiple burns on the same anatomical site and on the same side but of different degrees, identify the highest degree recorded in the diagnosis and assign only that code to the anatomical area
- Add an external cause code to identify the source, place, and intent of the burn. However, some insurance companies may not recognize or accept these codes

Burn site and depth (T20-T25)

T20: Head, neck, and face*

Anatomical site	2nd degree	3rd degree
Unspecified site of head, neck, and face	T20.20XX	T20.30XX
Right ear	T20.211X	T20.311X
Left ear	T20.212X	T20.312X
Unspecified ear	T20.219X	T20.319X
Lips	T20.22XX	T20.32XX
Chin	T20.23XX	T20.33XX
Nose	T20.24XX	T20.34XX
Scalp	T20.25XX	T20.35XX
Forehead and cheek	T20.26XX	T20.36XX
Neck	T20.27XX	T20.37XX
Multiple sites of head, neck, and face	T20.29XX	T20.39XX

T21: Trunk*

Anatomical site	2nd degree	3rd degree
Unspecified site of trunk	T21.20XX	T21.30XX
Chest wall	T21.21XX	T21.31XX
Abdominal wall	T21.22XX	T21.32XX
Upper back	T21.23XX	T21.33XX
Lower back	T21.24XX	T21.34XX
Buttocks	T21.25XX	T21.35XX
Male genital region	T21.26XX	T21.36XX
Female genital region	T21.27XX	T21.37XX
Other site of trunk	T21.29XX	T21.39XX

*Refer to the ICD-10-CM official guidelines for coding and reporting for information about the seventh character requirement.

You are ultimately responsible for determining appropriate reimbursement strategies and billing codes. The information in this document is for informational purposes only.

SELECT IMPORTANT SAFETY INFORMATION

Warnings and Precautions

- StrataGraft contains glycerin. Avoid glycerin in patients with known sensitivity (irritant reaction) to glycerin.
- Severe hypersensitivity reactions may occur. Monitor for both early and late symptoms and signs of hypersensitivity reaction following StrataGraft application, and treat according to standard medical practice.
- StrataGraft contains cells from human donors and may transmit infectious diseases or infectious agents, eg, viruses, bacteria, or other pathogens, including the agent that causes transmissible spongiform encephalopathy (TSE, also known as Creutzfeldt-Jakob disease [CJD or variant CJD]).

Please see additional Important Safety Information on page 7 and full [Prescribing Information](#).

Burn site and depth (T20-T25) (continued)

T22: Shoulder and upper limb*

Anatomical site	2nd degree	3rd degree
Unspecified site of shoulder and upper limb	T22.20XX	T22.30XX
Right forearm	T22.211X	T22.311X
Left forearm	T22.212X	T22.312X
Unspecified forearm	T22.219X	T22.319X
Right elbow	T22.221X	T22.321X
Left elbow	T22.222X	T22.322X
Unspecified elbow	T22.229X	T22.329X
Right upper arm	T22.231X	T22.331X
Left upper arm	T22.232X	T22.332X
Unspecified upper arm	T22.239X	T22.339X
Right axilla	T22.241X	T22.341X
Left axilla	T22.242X	T22.342X
Unspecified axilla	T22.249X	T22.349X
Right shoulder	T22.251X	T22.351X
Left shoulder	T22.252X	T22.352X
Unspecified shoulder	T22.259X	T22.359X
Right scapular region	T22.261X	T22.361X
Left scapular region	T22.262X	T22.362X
Unspecified scapular region	T22.269X	T22.369X
Multiple sites of right shoulder and upper limb	T22.291X	T22.391X
Multiple sites of left shoulder and upper limb	T22.292X	T22.392X
Multiple sites of unspecified shoulder and upper limb	T22.299X	T22.399X

*Refer to the ICD-10-CM official guidelines for coding and reporting for information about the seventh character requirement.

You are ultimately responsible for determining the appropriate reimbursement strategies and billing codes. The information contained in this document is provided for informational purposes only.

T23: Wrist and hand*

Anatomical site	2nd degree	3rd degree
Unspecified site	T23.20XX	T23.30XX
Right hand, unspecified site	T23.201X	T23.301X
Left hand, unspecified site	T23.202X	T23.302X
Unspecified hand, unspecified site	T23.209X	T23.309X
Right thumb	T23.211X	T23.311X
Left thumb	T23.212X	T23.312X
Unspecified thumb	T23.219X	T23.319X
Single right finger (except thumb)	T23.221X	T23.321X
Single left finger (except thumb)	T23.222X	T23.322X
Unspecified single finger	T23.229X	T23.329X
Multiple right fingers (except thumb)	T23.231X	T23.331X
Multiple left fingers (except thumb)	T23.232X	T23.332X
Unspecified multiple fingers (except thumb)	T23.239X	T23.339X
Multiple right fingers (including thumb)	T23.241X	T23.341X
Multiple left fingers (including thumb)	T23.242X	T23.342X
Unspecified multiple fingers (including thumb)	T23.249X	T23.349X
Right palm	T23.251X	T23.351X
Left palm	T23.252X	T23.352X
Unspecified palm	T23.259X	T23.359X
Back of right hand	T23.261X	T23.361X
Back of left hand	T23.262X	T23.362X
Back of unspecified hand	T23.269X	T23.369X
Right wrist	T23.271X	T23.371X
Left wrist	T23.272X	T23.372X
Unspecified wrist	T23.279X	T23.379X

Please see Important Safety Information on page 7 and full [Prescribing Information](#).

Burn site and depth (T20-T25) (continued)

T24: Lower limb*

Anatomical site	2nd degree	3rd degree
Unspecified site of right lower limb	T24.201X	T24.301X
Unspecified site of left lower limb	T24.202X	T24.302X
Unspecified site of unspecified lower limb	T24.209X	T24.309X
Right thigh	T24.211X	T24.311X
Left thigh	T24.212X	T24.312X
Unspecified thigh	T24.219X	T24.319X
Right knee	T24.221X	T24.321X
Left knee	T24.222X	T24.322X
Unspecified knee	T24.229X	T24.329X
Right lower leg	T24.231X	T24.331X
Left lower leg	T24.232X	T24.332X
Unspecified lower leg	T24.239X	T24.339X
Multiple sites of right lower limb	T24.291X	T24.391X
Multiple sites of left lower limb	T24.292X	T24.392X
Multiple sites of unspecified lower limb	T24.299X	T24.399X

T25: Ankle and foot*

Anatomical site	2nd degree	3rd degree
Right ankle	T25.211X	T25.311X
Left ankle	T25.212X	T25.312X
Unspecified ankle	T25.219X	T25.319X
Right foot	T25.221X	T25.321X
Left foot	T25.222X	T25.322X
Unspecified foot	T25.229X	T25.329X
Right toe(s)	T25.231X	T25.331X
Left toe(s)	T25.232X	T25.332X
Unspecified toe(s)	T25.239X	T25.339X
Multiple sites of right ankle and foot	T25.291X	T25.391X
Multiple sites of left ankle and foot	T25.292X	T25.392X
Multiple sites of unspecified ankle and foot	T25.299X	T25.399X

*Refer to the ICD-10-CM official guidelines for coding and reporting for information about the seventh character requirement.

Extent of thermal burn (T31)

T31

Body surface burned	ICD-10-CM code/ code range	With % of third-degree burns (indicated in last character)	
Less than 10%	T31.0		
10%-19%	T31.10 - T31.11	0	0%-9%
20%-29%	T31.20 - T31.22	1	10%-19%
30%-39%	T31.30 - T31.33	2	20%-29%
40%-49%	T31.40 - T31.44	3	30%-39%
50%-59%	T31.50 - T31.55	4	40%-49%
60%-69%	T31.60 - T31.66	5	50%-59%
70%-79%	T31.70 - T31.77	6	60%-69%
80%-89%	T31.80 - T31.88	7	70%-79%
90% or more	T31.90 - T31.99	8	80%-89%
		9	90% or more

The percentage of total body surface area (TBSA) burned is one of the ways the amount of area affected by a burn is measured. When calculating the extent of a burn injury, only second- and third-degree burns are considered.

Codes from category T31 “Burns classified according to extent of body surface involved” are to be used as primary diagnosis codes only when the site of the burn is unspecified. T31 codes are secondary diagnosis codes when T20-T25 codes specify the burn site.

You are ultimately responsible for determining appropriate reimbursement strategies and billing codes. The information in this document is for informational purposes only.

Please see Important Safety Information on page 7 and full [Prescribing Information](#).

MS-DRG ASSIGNMENTS⁵

Medicare reimburses hospitals for inpatient services using Medicare Severity Diagnosis-Related Groups (MS-DRGs) that have predetermined payment rates. Common MS-DRGs for patients admitted for burn treatment with StrataGraft are located in Major Diagnostic Category (MDC) 22, Burns. The hospital's actual payment rate under the assigned MS-DRG is influenced by a number of variables, including the area wage index, medical residency teaching activity, and volume of care to low-income patients.

Commercial insurers most commonly pay for inpatient hospital services on the basis of a percentage of charges, included in a DRG rate, or included in a per diem rate.

MS-DRG	Descriptor
927	Extensive burns or full thickness burns with MV >96 hours with skin graft
928	Full thickness burn with skin graft or inhalation injury with CC/MCC
929	Full thickness burn with skin graft or inhalation injury without CC/MCC
935	Non-extensive burns

Abbreviations: CC, complication or comorbidity; MCC, major complication or comorbidity; MV, mechanical ventilation.

REVENUE CODES⁶

Revenue codes identify the department in which the service was given, the types of services provided, or the supplies used. Most payers require that a valid procedure code be accompanied by a revenue code. Revenue codes include 4 digits; the first digit is typically a zero, and many insurance providers will assume a zero for the first digit rather than require it to be listed.

Revenue code	Descriptor
0636	Drugs requiring specific information

NDC⁷

In some cases, the NDC number is required on an inpatient or outpatient claim. NDCs are universal product identifiers assigned to drugs and biologics upon FDA approval. Many NDCs are displayed on drug packaging in a 10-digit format. Proper billing of an NDC requires an 11-digit number in a 5-4-2 format.

The NDC for StrataGraft is 73612-200-01 (10-digit format). With the addition of a leading zero, it is converted to 73612-0200-01 (11-digit format). Payer requirements regarding the use of the 10- or 11-digit NDC may vary.

You are ultimately responsible for determining the appropriate reimbursement strategies and billing codes. The information contained in this document is provided for informational purposes only. We strongly recommend that you consult your payer organization with regard to its reimbursement policies.

SELECT IMPORTANT SAFETY INFORMATION

Warnings and Precautions (continued)

StrataGraft is a xenotransplantation product because of an historic exposure of the keratinocyte cells to well-characterized mouse cells. The cell banks have been tested and found to be free of detectable adventitious agents, and mouse cells are not used in the manufacture of StrataGraft; however, these measures do not entirely eliminate the risk of transmitting infectious diseases and disease agents.

Transmission of infectious diseases or agents by StrataGraft has not been reported.

- Because StrataGraft is a xenotransplantation product, StrataGraft recipients should not donate whole blood, blood components, plasma, leukocytes, tissues, breast milk, ova, sperm, or other body parts for use in humans.

Adverse Reactions

- The most common adverse reactions (incidence $\geq 2\%$) were itching (pruritus), blisters, hypertrophic scar, and impaired healing. Other adverse events reported are included in the full Prescribing Information.

Pediatric Use

- The safety and effectiveness of StrataGraft in pediatric patients (<18 years) have not been established.

Please see additional Important Safety Information on page 7 and full [Prescribing Information](#).

INDICATION

StrataGraft® is an allogeneic cellularized scaffold product indicated for the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns).

IMPORTANT SAFETY INFORMATION

Contraindications

- Do not use in patients with known allergies to murine collagen or products containing ingredients of bovine or porcine origin.

Warnings and Precautions

- StrataGraft contains glycerin. Avoid glycerin in patients with known sensitivity (irritant reaction) to glycerin.
- Severe hypersensitivity reactions may occur. Monitor for both early and late symptoms and signs of hypersensitivity reaction following StrataGraft application, and treat according to standard medical practice.
- StrataGraft contains cells from human donors and may transmit infectious diseases or infectious agents, eg, viruses, bacteria, or other pathogens, including the agent that causes transmissible spongiform encephalopathy (TSE, also known as Creutzfeldt-Jakob disease [CJD or variant CJD]).

StrataGraft is a xenotransplantation product because of an historic exposure of the keratinocyte cells to well-characterized mouse cells. The cell banks have been tested and found to be free of detectable adventitious agents, and mouse cells are not used in the manufacture of StrataGraft; however, these measures do not entirely eliminate the risk of transmitting infectious diseases and disease agents.

Transmission of infectious diseases or agents by StrataGraft has not been reported.

- Because StrataGraft is a xenotransplantation product, StrataGraft recipients should not donate whole blood, blood components, plasma, leukocytes, tissues, breast milk, ova, sperm, or other body parts for use in humans.

Adverse Reactions

- The most common adverse reactions (incidence $\geq 2\%$) were itching (pruritus), blisters, hypertrophic scar, and impaired healing. Other adverse events reported are included in the full Prescribing Information.

Pediatric Use

- The safety and effectiveness of StrataGraft in pediatric patients (<18 years) have not been established.

Please see full [Prescribing Information](#).



For more information, visit [StrataGraft.com](https://www.stratagraft.com) or call 1-877-647-2239 for additional support

REFERENCES

1. Medicare program; hospital inpatient prospective payment systems for acute care hospitals and the long-term care hospital prospective payment system and policy changes and fiscal year 2022 rates; quality programs and Medicare promoting interoperability program requirements for eligible hospitals and critical access hospitals; changes to Medicaid provider enrollment; and changes to the Medicare shared savings program. *Fed Regist.* 2021;86(154):45079-45090. To be codified at 42 CFR 412, 413.
2. 2022 ICD-10-PCS. Centers for Medicare & Medicaid Services. Updated June 4, 2021. Accessed September 14, 2021. <https://www.cms.gov/medicare/icd-10/2022-icd-10-pcs>.
3. 2022 ICD-10-CM. Centers for Medicare & Medicaid Services. Updated August 10, 2021. Accessed September 14, 2021. <https://www.cms.gov/medicare/icd-10/2022-icd-10-cm>.
4. ICD-10-CM Official Guidelines for Coding and Reporting FY 2022 (October 1, 2021 - September 30, 2022). Centers for Medicare & Medicaid Services. Accessed September 14, 2021. <https://www.cms.gov/files/document/fy-2022-icd-10-cm-coding-guidelines.pdf>.
5. MDC 22 Burns. In: *ICD-10-CM/PCS MS-DRG v38.0 Definitions Manual*. Centers for Medicare & Medicaid Services. 2020. Accessed September 14, 2021. https://www.cms.gov/icd10m/version38-fullcode-cms/fullcode_cms/P0025.html.
6. Completing and processing the form CMS-1450 data set. In: *Medicare Claims Processing Manual*. Centers for Medicare & Medicaid Services; 2019:chap 25. Accessed September 14, 2021. <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c25.pdf>.
7. StrataGraft. Package insert. Stratatech Corporation; 2021.